Sarepta Therapeutics Inc (SRPT)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 83.22% | 87.91% | 85.00% | 86.17% | 88.26% |
| Operating profit margin | 11.47% | -21.54% | -57.47% | -64.07% | -104.46% |
| Pretax margin | 13.71% | -41.83% | -73.95% | -59.69% | -102.40% |
| Net profit margin | 12.37% | -43.11% | -75.40% | -59.66% | -102.60% |
1. Gross Profit Margin: Sarepta Therapeutics Inc experienced a slight decrease in its gross profit margin from 88.26% in 2020 to 83.22% in 2024. This indicates that the company's ability to generate profit from its core operations has declined over the period.
2. Operating Profit Margin: The operating profit margin of Sarepta Therapeutics Inc showed a significant improvement from negative percentages in 2020 and 2021 to a positive 11.47% in 2024. This suggests that the company has been able to control its operating expenses and improve operational efficiency, leading to a profitability turnaround in recent years.
3. Pretax Margin: The pretax margin also displayed a notable recovery trend, moving from negative percentages in 2020 and 2021 to a positive 13.71% in 2024. This indicates that the company has been successful in managing its pre-tax income and expenses more effectively, resulting in improved profitability before tax.
4. Net Profit Margin: Sarepta Therapeutics Inc's net profit margin witnessed a remarkable improvement from negative figures in 2020 and 2021 to a positive 12.37% in 2024. This signifies that the company has been able to enhance its bottom line profitability by efficiently managing its net income in relation to its revenue, reflecting better financial health and performance.
Overall, Sarepta Therapeutics Inc has shown positive signs of profitability recovery and enhancement in recent years, as indicated by the improvement in its operating, pretax, and net profit margins. However, the slight decline in the gross profit margin may warrant further examination to ensure sustainable profitability in the future.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.50% | -8.20% | -17.14% | -14.29% | -18.90% |
| Return on assets (ROA) | 5.94% | -16.42% | -22.49% | -13.30% | -18.57% |
| Return on total capital | 18.27% | -57.96% | -165.40% | -38.30% | -64.73% |
| Return on equity (ROE) | 15.40% | -62.37% | -182.75% | -45.13% | -72.74% |
Sarepta Therapeutics Inc's profitability ratios depict a fluctuating performance over the years.
- Operating Return on Assets (Operating ROA): The company experienced negative operating ROA in the range of -8.20% to -18.90% from 2020 to 2024. Although the ratio improved from 2023 to 2024, it suggests that the company's core operations were not efficiently generating profits relative to its total assets during most of the period.
- Return on Assets (ROA): ROA also demonstrated variability, with negative values ranging from -16.42% to -22.49% up until 2023, indicating that overall asset utilization to generate profits was not efficient. However, the ratio turned positive in 2024 at 5.94%, signifying an improvement in the company's ability to generate earnings relative to its total assets.
- Return on Total Capital: The return on total capital was negative in the range of -38.30% to -165.40% from 2020 to 2023, indicating that the company was unable to generate returns exceeding the total capital employed during these years. Notably, there was a significant improvement in 2024, with a positive return of 18.27%, indicating a more efficient utilization of total capital to generate profits.
- Return on Equity (ROE): ROE ranged from -45.13% to -182.75% during the period analyzed, highlighting the company's inability to generate positive returns for its shareholders relative to the equity invested. The positive turn in 2024, with an ROE of 15.40%, suggests an improvement in shareholder value creation.
Overall, the profitability ratios demonstrate a mix of negative and positive performance trends, with signs of improvement in certain metrics, particularly in 2024. Further analysis of the company's financial health and operational efficiency would be necessary to provide a more in-depth assessment.